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Abstract:  We  demonstrate  for  the  first  time  that  optical  coherence 
tomography (OCT) imaging can reliably distinguish between morphologic 
features  of  low  risk  pancreatic  cysts  (i.e.,  pseudocysts  and  serous 
cystadenomas)  and  high  risk  pancreatic  cysts  (i.e.,  mucinous  cystic 
neoplasms  and  intraductal  papillary  mucinous  neoplasms).  In  our  study 
fresh  pancreatectomy  specimens  (66)  from  patients  with  cystic  lesions 
undergoing surgery were acquired and examined with OCT. A training set 
of  20  pathology-OCT  correlated  tissue  specimens  were  used  to  develop 
criteria  for  differentiating  between  low  and  high  risk  cystic  lesions.  A 
separate (validation) set of 46 specimens were used to test the OCT criteria 
by  three  clinicians,  blinded  to  histopathology  findings.  Histology  was 
finally used as a „gold‟ standard for testing OCT findings. OCT was able to 
reveal  specific  morphologic  features  of  pancreatic  cysts  and  thus  to 
differentiate between low-risk and high-risk cysts with over 95% sensitivity 
and  specificity.  This  pilot  study  suggests  that  OCT  could  be  used  by 
clinicians in the future to more reliably differentiate between benign and 
potentially  malignant  pancreatic  cysts.  However,  in  vivo  use  of  OCT 
requires  a  probe  that  has  to  fit  the  bore  of  the  pancreas  biopsy  needle. 
Therefore, we have developed such probes and planned to start an in vivo 
pilot study within the very near future. 
© 2011 Optical Society of America 
OCIS codes: (170.0170) Medical optics and biotechnology; (170.4580) Optical diagnostics for 
medicine; (170.4500) Optical coherence tomography; (170.6935) Tissue characterization. 
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1. Introduction 
Pancreatic  cystic  lesions  represent  an  increasingly  common  diagnostic  and  therapeutic 
challenge  [1].  A  significant  number  of  pancreatic  cysts  are  detected  incidentally  when 
noninvasive abdominal imaging is performed for unrelated diagnosis [2]. The differentiation 
between low- and high-risk lesions is difficult with traditional imaging [3]. Low-risk lesions 
(simple  cysts,  pseudocysts,  and  serous  cystadenomas  [SCAs])  are  generally  not  resected 
because they have no risk or an extremely low risk of malignant transformation [4]. High-risk 
lesions  are  mucin-producing  tumors  (mucinous  cystic  neoplasms  [MCNs]  and  intraductal 
papillary  mucinous  neoplasms  [IPMNs])  and  cystic  solid  tumors  (papillary  cystic  tumors, 
cystic ductal adenocarcinoma, and islet cell tumor) [5]. Depending on degree of dysplasia [6], 
MCNs  and  IPMNs  are  classified  as  adenoma,  borderline,  carcinoma  in  situ,  or  invasive 
cancer. 
An accurate diagnosis of a pancreatic cystic lesion is often difficult because traditional 
cross-sectional imaging tests cannot provide diagnostic resolution images [7]. Traditionally, 
computed tomography (CT) has been used as a first line of diagnosis for cystic neoplastic 
lesions of the pancreas. However, the limited resolution of CT scanning prevents reliable 
differentiation of the pancreatic cysts [8]. More recently endoscopic ultrasound (EUS) has 
been used to image the pancreas with improved resolution. Because the pancreas lies directly 
adjacent to the stomach, an EUS transducer can be placed in close proximity to the pancreas, 
and the entire gland can be readily imaged. Although EUS is well suited for assessment of 
cystic lesions because it can provide images of the cystic wall and septations, it has not been 
able to accurately differentiate between benign and malignant cystic neoplasms [9]. Either of 
these techniques can be supplemented by the use of fine needle aspiration (FNA) cytology for 
diagnostic yield enhancement. However, the results of cyst fluid analysis have been somewhat 
disappointing [10]. Although EUS-guided FNA of pancreatic masses is a highly sensitive test 
for diagnosing pancreatic malignancy, the results of FNA of pancreatic cysts have not been as 
successful [11]. Obtaining sufficient cells for diagnostic cytology is often difficult because of 
the  relatively  low  cellularity  of  aspirated  pancreatic  cyst  fluid  [12–14].  Therefore,  the 
accuracy of EUS-FNA can still vary over a relatively large range (69% to 100%). 
Recently,  optical  coherence  tomography  (OCT),  a  high  resolution  structural  imaging 
technology  based  on  low  coherence  interferometry,  has  shown  great  promise  in  disease 
diagnosis, including differentiation between benign and malignant lesions [15]. OCT is an 
interferometric technique, typically employing near-infrared light, and allows for achieving 
micron-scale cross-sectional images of the biological samples [16]. The use of relatively long 
wavelength light allows it to penetrate up to 2 mm into a highly scattering media, such as 
biological samples. OCT images are somewhat similar to those provided by conventional 
ultrasound,  but  OCT  provides  at  least  one  order  of  magnitude  increase  in  the  resolution. 
However, the main drawback of this technology is that its field of view is limited to several 
mm. 
OCT  studies  in  various  organs  have  demonstrated  the  ability  of  OCT  to  differentiate 
between  normal  and  pre-malignant  conditions.  For  example,  ovarian  cysts,  masses,  and 
abnormal  tissue  have  been  successfully  imaged  with  laparoscopic  OCT  [17].  Laryngeal 
dysplasia  and  malignancy  have  been  successfully  imaged  with  OCT  probes  during 
laryngoscopy [18]. Malignant and inflammatory lymph nodes have been differentiated with 
OCT [19]. Early investigations using bronchoscopic OCT probes have also demonstrated the 
ability of OCT to diagnose lung cancer [20]. Intestinal metaplasia and dysplastic Barrett‟s 
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the pancreas have also demonstrated the ability of this technology to distinguish the layers of 
the main duct epithelium in inflammatory and malignant diseases [22]. 
This  paper  presents  the  results  of  a  pilot  study  that  had  the  goal  to  investigate  the 
possibility of using OCT imaging for differentiating between morphologic features of low risk 
pancreatic cysts (i.e. pseudocysts and SCAs) and high risk pancreatic cysts (i.e., MCNs and 
IPMNs). We hypothesized that OCT imaging could be used to more reliably differentiate 
between two classes of pancreatic cysts: mucinous and serous. 
2. Materials and Methods 
2.1 OCT Instrumentation 
An OCT system based on the Fourier domain approach [23], developed by Physical Sciences, 
Inc.  (PSI),  was  used  for  this  study.  A  simplified  schematic  and  a  photograph  of  this 
instrument are shown in Fig. 1. It uses a swept-source (Model HSL-1000, SANTEC, Japan) 
with a central wavelength of 1310 nm, a bandwidth of about 89 nm, and a scanning frequency 
of 20 kHz. The light from the swept source is sent to a fiber optic interferometer that uses a 
circulator in the input arm to maximize the amount of light that is transmitted to the sample 
and  also  the  amount  of  light  reflected  back  from  the  sample.  A  fraction  of  the  light 
backscattered from the sample passes back through the probe into the interferometer, where it 
mixes with a reference beam to produce interference fringes. A balanced detection scheme is 
used in the detection arm of the interferometer. Balanced detection helps to minimize the 
intensity noise of the light source. The balanced detector (Model 1817FC, New Focus) has a 
bandwidth of 80 MHz and a 5x10
4 V/A transimpedance gain of 5 x 10
4V/A. The output of the 
detector is digitized with a PSI custom-made high-speed and very low noise digitizer (50 
Megasamples/sec digitization rate). The signal at the output of the digitizer is sent to a custom 
real-time digital signal processing (DSP) board, also custom-designed and fabricated by PSI, 
which performs the fast Fourier transform of the signal to obtain the depth reflectivity profile 
of  the  sample.  Detailed  description  of  the  digitization  and  signal  processing  boards  was 
presented  elsewhere  [24].  A  LabView-based  software  program  is  used  for  displaying  the 
processed OCT images on the computer screen and for configuring the real time board. 
 
Fig. 1. Simplified schematic (A) and photograph of the OCT system (B). 
The OCT system was integrated within a 19 inch wheeled rack, which allowed for easy 
rolling in and out of the imaging room of the hospital. A benchtop OCT probe was used to 
image the surface of the cyst. The OCT probe had an OCT port and a laser port, as shown in 
the schematic from Fig. 1. The laser port was used to send a visible aiming beam (635 nm) 
and visualize the position of the near-infrared OCT beam on the tissue surface. The bench-top 
imaging probe also contained a pair of galvanometers, which allowed for generating a raster 
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objective scan lens (LSM03, Thorlabs, NJ). This system provided an axial resolution of 9.5 
μm (in air), which is close to the theoretical value of 8.5 μm, and a lateral resolution of 25 μm. 
A scanning range of maximum 5 mm was used on both dimensions with this probe. Each 
OCT  frame  (B-scan)  contained  1024  A-lines,  while  each  raster  (C-scan)  contained  256 
frames. 
2.2 OCT Imaging of Tissue Specimens 
A human protocol for this study was approved by the MGH Human Research Committee to 
analyze  the  correlation  between  the  OCT  images  and  the  histologic  appearance  of  the 
pancreatic surgical specimens from patients who had a surgical resection at the Massachusetts 
General Hospital. No patient identifiers were provided to the investigators of this study. 
Fresh  pancreatic  tissue  specimens  (pancreatic  cysts)  were  made  available  immediately 
after  surgery.  The  cysts  were  transected  along  the  long  axis  to  fully  expose  the  luminal 
surface. The cystic tissue was then placed on a Petri dish in a saline bath to keep it moist. A 
pair of linear positioning stages was used for proper positioning of the tissue specimen under 
the  OCT  imaging  objective.  For  correct  imaging-histology  co-registration,  a  visible-light 
guiding-beam (635-nm laser diode) that was coincident with the near-infrared interrogating 
OCT beam was used. The targeted imaging site of the cyst epithelium surface was labeled 
with India ink in order to perform histopathology correlation with the OCT findings. OCT 
tomography imaging of India ink labeled cyst surface was performed to test OCT capability 
for revealing the detailed anatomy of cystic wall, as well as of the cyst fluid. Representative 
OCT images of the tissue  morphology  were collected and saved  for later histopathologic 
correlation. 
2.3 Histopathologic Examination 
After completion of the OCT examination, the specimens were fixed with 10% formalin and 
embedded in paraffin. Tissue sections were then obtained and stained with hematoxylin and 
eosin  for  routine  histopathologic  examination.  The  histopathologic  diagnostic  criteria  of 
pancreatic cysts were based on the World Health Organization classification system [25]. All 
sections were examined and characteristic histopathologic findings were noted independently 
by an experienced GI pathologist blinded to the OCT findings. 
2.4 Data Analysis 
Based on histology results, the cysts were prospectively divided into two groups, mucinous 
(MCNs and IPMNs) and non-mucinous (SCAs and others). The initial analysis of OCT and 
histology  results  was  performed  by  independent  investigators,  blinded  to  each  other's 
findings. A training set of 20 specimens, representative for both mucinous and non-mucinous 
lesions  were  selected  by  the  study  coordinator  (SC)  and  OCT-histology  correlation  was 
performed. The characteristic OCT features for each type of pancreatic cystic lesions from the 
training  set  were  standardized  and  defined  as  “OCT  criteria”  for  differentiation  of  cystic 
lesions. The remaining set of 46 tissue specimens was then attributed to the validation study. 
The standard OCT criteria were prospectively applied to OCT images from this set by three 
clinicians blinded to histopathological findings. The clinicians were asked to assign each OCT 
image to one of four different categories: „MCN‟, „IPMN‟, „SCA‟, and „other‟. After that, 
correlation with histology results was performed. Out of the total 46 samples, 26 were found 
to be serous after histologic examination, while the remaining 20 were found to be mucinous. 
All data  were entered and stored in a computerized database designed  with Microsoft 
Excel  2000.  Specificity,  sensitivity,  and  accuracy  were  calculated  for  each  observer.  The 
histology was used as the „gold‟ standard for classifying the cysts into two groups, mucinous 
and non-mucinous. The sensitivity and the specificity of the findings were calculated using 
the  following  formulas:  Sensitivity  =  TP/(TP  +  FN);  Specificity  =  TN/(TN  +  FP).  True 
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while true negative (TN) interpretation reflected the accurate diagnosis of a non-mucinous 
lesion.  False  positive  (FP)  reflected  incorrectly  identified  mucinous  lesions,  while  false 
negative  (FN)  reflected  incorrectly  identified  serous  lesions.  The  Positive  and  Negative 
Predictive values were calculated as well using the following formulas: PPV = TP/(TP + FP); 
NPV = TN/(TN + FN). 
Inter-observer agreement of overall OCT prediction for differentiation of cystic lesions 
among  the  three  readers  and  agreement  between  the  overall  OCT  diagnosis  and 
histopathologic  type  (for  the  three  readers)  were  studied  using  the  kappa  statistic.  Kappa 
statistical results were classified as follows: less than chance agreement (<0), slight agreement 
(0.01-0.2), fair agreement (0.21-0.4), moderate agreement (0.41-0.6), substantial agreement 
(0.61-0.8), and almost perfect agreement (0.81-0.99). 
3. Results 
The  OCT  images  of  each  tissue  specimen  were  correlated  with  histological  findings  by 
identifying India ink marks, as well as notable and unique features of each tissue type. 
The  OCT  images  of  most  of  the  microcystic  SCAs  were  remarkably  similar  and  all 
demonstrated  multiple  tiny  cysts  with  well-defined  outlines  (Fig.  2(A)).  The  thin  septae 
between the cysts showed homogenously high scattering, creating a honeycomb appearance. 
Significantly,  the  cyst  contents  were  homogenously  dark  and  lacked  scattering  effect. 
Histologically,  this  appearance  correlated  with  the  microcystic  appearance  of  a  serous 
cystadenoma (Fig. 2(A′)). In a single case, focal intraluminal scattering was noted on OCT 
(Fig. 2(B)), and this corresponded to a focus of fresh intraluminal hemorrhage shown in the 
histological appearance (Fig. 2(B′)). 
 
Fig.  2.  OCT  appearance  of  SCAs  (A)  and  (B)  and  corresponding  histology  (A',  B').  The 
microcystic SCAs show multiple tiny cysts with well-defined outlines. The thin septae between 
the cysts (see arrow), creating a honeycomb appearance, shows homogenously high scattering. 
The cyst content usually lacks a scattering effect. Focal intraluminal scattering can be noted on 
some cysts (see asterisk in Fig. 2(B)) and it usually corresponds to a focus of intraluminal 
hemorrhage, as confirmed by histology (see red area Fig. 2(B′)). OCT scale bar = 500 μm. 
Raster  scans of these cysts  were  taken as  well to determine their 3D appearance.  An 
example  of  a  scan  through  a  typical  microcystic  SCA  is  shown  in  the  Media  1.  Two 
representative slides (enface and cross-sectional) of this benign cyst are shown in Fig. 3. The 
enface view is shown on the left side of Fig. 3, while a perpendicular cross-section in the 
position indicated by the line from the enface view is shown on the right side of Fig. 3. Both 
views show the thin septae between the microcysts, which creates a honeycomb appearance. 
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homogenously dark due to lack of scattering structures (clear fluid). 
 
Fig. 3. (Media 1). Fly-through video of a SCA. (A) Enface view at a depth indicated by the line 
from the cross-sectional image. (B) cross-sectional view. The raw video was acquired at 20 fps. 
Scale bar = 500 μm. 
The OCT images of MCNs  (Fig. 4) demonstrated several 'daughter' cysts (see  yellow 
arrow) within the rind of tissue surrounding the dominant unilocular cyst (see red arrow). 
Unlike SCAs, there was high scattering within the lumen of these cysts, and on histology this 
appearance  corresponded  to intraluminal  mucin  (Fig.  3  right).  Furthermore,  unlike  SCAs, 
these  cysts  were  separated  by  large  amount  of  homogenous  high  scattering  tissue  that 
corresponded to the intervening fibrocollagenous tissue. 
Raster scans of these cysts were also taken to visualize their 3D appearance. An example 
of a scan through a typical MCN is shown in the Media 2. Two representative slides (enface 
and cross-sectional) of this potentially malignant cyst are shown in Fig. 5. The enface view is 
shown on the left side of Fig. 5, while a perpendicular cross-section in the position indicated 
by the line from the enface view is shown on the right side of Fig. 5. Both views show the 
presence of the thicker microcystic wall than in the SCA case and a highly scattering fluid 
(mucin). The scattering is thought to come by the presence of the dead exfoliating cells from 
the thick cystic epithelium. 
 
Fig. 4. OCT appearance of a mucinous cyst (A) and corresponding histology (B). Yellow 
arrows indicate the presence of smaller size (daughter) cysts, while the red arrow indicates the 
main cystic cavity. The cystic content (mucin) shows some scattering due the presence of dead 
epithelial cells. OCT scale bar = 500 μm. 
 
Fig. 5. (Media 2). Fly-through video of a MCN. (A) Enface view at a depth indicated by the 
line from the cross-sectional view. (B) Cross-sectional view. The raw video was acquired at 20 
fps. Scale bar = 500 μm. 
The  OCT  images  of  IPMNs  (Fig.  6(A))  were  similar  to  those  of  MCNs  in  that  they 
demonstrated multiple cysts with heterogeneous intraluminal medium to high scattering that 
corresponded to mucin content seen in the histological appearance (Fig. 6(B′)). However, the 
cysts were smaller in size and large unilocular cysts were not found. 
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Fig. 6. OCT appearance of mucinous IPMN cysts (A), magnified ROI (B), and corresponding 
histology (B'). Yellow arrows indicate the areas of highly scattering mucin within the cyst 
fluid. OCT Scale bar = 500 μm. 
Raster scans were taken as well for these cysts. An example of a scan through a typical 
IPMN is shown in the Media 3. Two representative slides (enface and cross-sectional) of this 
potentially malignant cyst are shown in Fig. 7. The enface view (on the left) was taken at a 
depth indicated by a line in the vertical cross-section (on the right). The line in the enface 
image  shows the position  where  the perpendicular cross-sectional image  was taken.  Both 
views show the presence small size microcysts, very close to the cyst surface. The microcysts 
are  separated  by  larger  amounts  of  tissue  than  in  the  case  of  microcystic  SCAs.  The 
microcysts contain a highly scattering fluid, similar to MCNs. 
 
Fig. 7. (Media 3). Fly-through video of a IPMN. (A) Enface view. (B) Cross-sectional view. 
The raw video was acquired at 20 fps. Scale bar = 500 μm. 
OCT criteria for differentiating between MCNs, SCAs, and IPMNs were developed using 
OCT images from representative cystic lesions from a set of 20 tissue samples (training set), 
which were selected by the histopathologist. The main characteristics of each type of cystic 
lesion are shown in Fig. 8. As it can be observed, these criteria are mainly based on the visual 
appearance of the cystic wall morphology and on the scattering properties of the cystic fluid. 
Although relatively simple, they provided a very good discrimination between serous and 
mucinous  cysts.  Based  on  these  criteria,  randomly  selected  OCT  images  of  the  46  tissue 
specimens (validation set) were independently evaluated by a gastroenterologist, a radiologist 
and a pathologist. The investigators were asked to review each OCT image and assign the 
image to one of 4 categories (MCN, IPMN, SCN, other). OCT results were judged against 
histopathology findings. Using histology as the „gold‟ standard for correctly diagnosing each 
type of cyst, the rates of sensitivity, specificity were determined for OCT. 
The  summary  of  the  OCT-histology  correlation  analysis  is  shown  in  Table  1.  High 
sensitivities (95.6% for gastroenterologist and 100% for radiologist and pathologist)  were 
obtained for distinguishing between mucinous and non-mucinous cystic lesions. However, of 
these  successfully  distinguished  mucinous  cystic  lesions,  only  the  radiologist  accurately 
(100% sensitivity and 85% specificity) distinguished IPMNs from MCNs. Nevertheless, all 
three physicians were moderately successful identifying MCNs with a specificity of 85% for 
the radiologist and 92% for both the gastroenterologist and pathologist. 
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Fig. 8. OCT diagnostic criteria for pancreatic cysts. 
Kappa statistics, also presented in  Table 1, suggest that  all three physicians exhibited 
“almost perfect” overall agreement in distinguishing mucinous cystic lesions with kappa = 
0.95  between  radiologist  and  gastroenterologist  agreement,  and  kappa  =  0.95  between 
radiologist and pathologist agreement. Agreement between gastroenterologist and pathologist 
was slightly lower with a kappa statistic of 0.91. 
Table 1. Sensitivity, Specificity, and Kappa Analysis 
SENSITIVITY AND SPECIFICITY ANALYSIS 
Mucinous vs. Non-mucinous 
Reviewer  Gastroenterologist  Radiologist  Pathologist 
Sensitivity(%)  95.6 (78, 100)  100 (85, 100)  100 (85, 100) 
Specificity (%)  100 (85, 100)  100 (85, 100)  95.6 (78, 100) 
Negative Predictive Value (%)  95.8 (79, 100)  100 (85, 100)  100 (85, 100) 
Positive Predictive Value (%)  100 (85, 100)  100 (85, 100)  95.8 (79, 100) 
IPMNs vs. MCNs 
Sensitivity(%)  50 (19, 81)  100 (69, 100)  30 (0.07, 65) 
Specificity (%)  92 (62, 100)  85 (55, 98)  92(64, 100) 
Negative Predictive Value (%)  83 (36, 100)  83 52, 98)  75 (19, 99) 
Positive Predictive Value (%)  69 (41, 89)  100 (72, 100)  63 (38, 84) 
KAPPA ANALYSIS 
  Kappa  95% LCL 
(Lower Confidence 
Limit) 
95% UCL 
(Upper Confidence 
Limit) 
Radiologist x Gastroenterologist  0.957  0.872  1.000 
Gastroenterologist x Pathologist  0.913  0.796  1.000 
Radiologist x Pathologist  0.957  0.872  1.000 
4. Discussion and Conclusions 
The detection of pancreatic cystic lesions by cross sectional CT or MR imaging is dependent 
on the identification of a low attenuation area within the pancreas. CT and MRI are both 
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difficult  with  either  imaging  modality.  Despite  major  advances  in  imaging,  the  overall 
accuracy of cross sectional imaging for pancreatic cysts diagnosis remains rather low [26]. An 
accurate  CT  diagnosis  is  hampered  by  poor  resolution  of  septation  patterns  (macro  and 
microcystic morphology) [27,28]. In addition, nearly 20% of cysts that are classified based on 
septation  pattern  are  inaccurately  diagnosed  because  of  a  large  overlap  between  the 
macrocystic and microcystic morphology among both mucinous and non-mucinous cysts [28]. 
Endoscopic  ultrasound  (EUS)  imaging  provides  superior  accuracy  compared  to  CT.  In 
addition to enhanced resolution, it takes advantage of the close proximity of the ultrasound 
transducer to the pancreas. Therefore, ultrasound is more sensitive than CT and MRI in the 
detection  of  intracystic  septations  [29,30].  Nevertheless,  EUS  imaging  alone  still  has  a 
relatively low diagnostic rate in the differentiation of various cyst types [31]. The use of EUS-
FNA aspiration for fluid collection has enabled endoscopists to use the presence of tumor 
markers and abnormal cytology to supplement EUS imaging [11]. Despite these advances, the 
accuracy of EUS and cyst fluid analysis for the differentiation between mucinous and non-
mucinous cysts still remains modest [14,31,32]. 
We  have  evaluated  the  use  of  a  high  resolution  OCT  imaging  in  the  diagnosis  of 
pancreatic  cystic  lesions.  In  our  study,  we  performed  ex  vivo  pancreatic  imaging  using  a 
benchtop probe. Since previous OCT studies in various organs demonstrated the ability of 
OCT to differentiate between normal and pre-malignant conditions [17–21], we hypothesized 
that  OCT  might  also  be  able  to  differentiate  between  the  interior  structures  of  various 
pancreatic cystic lesions. Early investigations of OCT in the pancreas have also demonstrated 
the  ability  of  this  technology  to  distinguish  the  layers  of  the  main  duct  epithelium  in 
inflammatory and malignant diseases [22]. 
We have recently reported OCT use for imaging morphologic features of pancreatic cysts 
[33]. Similar to the methods used for the imaging of the intestinal metaplasia and dysplasia 
seen in Barrett‟s esophagus, we have placed a high resolution probe directly adjacent to the 
cut surface of the pancreatic cysts. Using a wide variety of pancreatic cysts, we were able to 
demonstrate excellent correlations between OCT images and the histologic features of serous 
cysts  and  microcystic  septations.  Along  similar  lines,  we  were  able  to  provide  some  key 
imaging  features  of  the  mucinous  cystic  lesions,  for  example,  the  high  scattering  of  the 
mucinous fluid and the presence of a large amount of homogenous high scattering tissue 
between  the  microcysts  that  corresponds  to  the  intervening  fibrocollagenous  tissue  the 
increased epithelial thickness of the malignant cysts. We found strong correlations between 
histology and OCT imaging in a learning set of images from twenty tissue specimens. In our 
initial phase of testing, we examined the accuracy and the correlation of OCT imaging with 
the  histological  appearance  of  the  cysts  based  on  an  unblinded  analysis.  Based  on  the 
experience  obtained  with  the  learning  set  of  OCT  images,  we  proceeded  with  a  blinded 
analysis  of  OCT  images  by  three  different  clinicians.  The  cysts  were  determined  to  be 
mucinous  or  non-mucinous  based  on  pre-established  OCT  criteria  and  the  results  were 
compared with histology findings. Despite modest training and little experience with OCT 
imaging, the three clinicians were able to identify mucinous cysts with high levels of accuracy 
(96-100%).  Furthermore,  there  was  very  good  consistency  as  demonstrated  with  Kappa 
statistics. 
Our preliminary study was limited to ex vivo imaging and had the goal of investigating the 
use of OCT imaging for differentiating between serous and mucinous pancreatic cysts. Cystic 
wall  morphology  and  scattering  of  the  cystic  fluid  were  the  main  features  used  for  cyst 
differentiation. However, additional features, like the thickness of the cystic epithelium could 
be used as well to determine the malignancy potential of the mucinous cysts or to aid in 
differentiating between serous and mucinous cysts. For example, a very difficult problem for 
the gastroenterologist is to differentiate between low grade and high grade MCNs/IPMNs. It 
is known from histological examination that high grade mucinous cysts have substantially 
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lower than 10 μm, and the epithelium does not suffer severe modifications while the cyst 
continues to grow. Unfortunately, the limited resolution of the OCT system did not provide 
very  reliable  differentiation  between  the  two  main  categories  of  analyzed  cysts  based  on 
epithelial thickness. Therefore, we have recently built another OCT system and endoscopic 
probe that will provide enhanced axial and lateral resolution (8 μm, and 20 μm respectively), 
and  thus  might  help  to  include  epithelial  features  in  our  criteria  for  cystic  lesions 
differentiation. 
Besides  imaging  resolution,  imaging  range  and  penetration  depth  are  two  important 
parameters that also need further attention. Unfortunately, the penetration depth for OCT is 
generally  limited  to  about  2  mm,  and  thus  only  a  small  area  of  the  cystic  lesion  can  be 
evaluated at the time, for a given position of the OCT probe within the cyst. Therefore, in vivo 
imaging will require OCT probe positioning in several different areas of the cyst to get a more 
complete picture of cyst morphology. With regard to the imaging range, it is desirable to 
investigate larger areas of cystic  microcavities  for a given localization of the OCT probe 
within the cyst. This is especially important for MCNs, which can have small size (hundreds 
of microns) daughter microcysts (microcavities), but also larger cavities on the order of tens 
of millimeters. However, although the imaging range of the OCT system can be made within 
the order of 6 to12 mm, the potential of imaging large cavities is limited by the relatively 
short working distance of the OCT probe. This parameter cannot be made too large (over 23 
mm) without compromising imaging lateral resolution, unless a dynamic focusing scheme is 
implemented. Therefore, we will further investigate various design approaches for the OCT 
probe before moving to an in vivo study. 
In  summary,  OCT  provided  high  resolution  images  of  the  cyst  morphology,  enabling 
clinicians to accurately differentiate between serous and mucinous cysts. Although imaging 
was performed in an ex vivo setting, our results suggest that there is a good likelihood that 
intra-cystic  OCT  imaging  with  a  minimally  invasive  probe  would  also  allow  for  reliable 
differentiation between serous and mucinous cysts. These findings are important because of 
the potential of OCT imaging to supplement the results of EUS. We are currently planning to 
perform a pilot in vivo study to further explore the potential of OCT imaging for aiding EUS-
FNA in differentiating between various cystic lesions of the pancreas. 
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